Skip to Main Content

Paper Details

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Cell Cycle
35
2018
5-azacytidine, ALCL, ALL, AML, AML cells, ATF4, Akt, Bcl-2 family members, Burkitt's lymphoma, Burkitt's lymphoma xenograft model, CHOP, CLL, CML, CTCL, DLBCL, Foxo3a, Hodgkin's lymphoma, IAP, MCL, MCL), MM, MM cells, MM, MCL and ALCL cells, ONC201, acute leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, advancer cancer, anaplastic large cell lymphoma, bortezomib, caspase, chronic lymphocytic leukemia, chronic myelogenous leukemia, cutaneous T-cell lymphoma, cyclin D1, cytarabine, dexamethasone, diffuse large B-cell lymphoma, hematological malignancies, imipridone, ixazomib, mantle cell lymphoma, multiple myeloma, multiple myeloma (MM) cell lines, non-Hodgkin's lymphoma, primary samples, tumor
Author NameAffiliation
Stephan A Gruppb The Children's Hospital of Philadelphia
Mathew J Garnette Wellcome Trust Sanger Institute
Ultan McDermotte Wellcome Trust Sanger Institute
Cyril H Benesf Massachusetts General Hospital, Harvard Medical School
Joshua E AllenInc.
  • 1 - 5

Datasets